| [February 05, 2013] |
 |
USANA Health Sciences Announces Record Fourth Quarter and Full-Year 2012 Financial Results
SALT LAKE CITY --(Business Wire)--
USANA Health Sciences, Inc. (NYSE: USNA) today announced record
financial results for its fiscal fourth quarter and full-year ended
December 29, 2012.
Financial Performance
Net sales for the fourth quarter of 2012 increased by 15.5% to $168.5
million, compared with $145.9 million in the prior-year period. The
growth in net sales was driven by increases in both the Company's Asia
Pacific and North America/Europe regions. Favorable changes in currency
exchange rates contributed approximately $3.0 million to the top line
for the quarter.
Net earnings for the fourth quarter increased to $18.4 million, an
improvement of 40.2%, compared with the prior-year period. This increase
was due primarily to higher net sales and lower relative Associate
incentive expense for the quarter, and was partially offset by lower
gross margins. Earnings per share for the quarter increased by 46.0% to
$1.27, compared with $0.87 in the fourth quarter of the prior year. This
improvement in earnings per share can be attributed to higher net
earnings and a lower number of diluted shares outstanding, which
resulted from the Company's share repurchases over the last 12 months.
Total diluted common shares outstanding as of December 29, 2012 were
14,471,000 compared with 15,177,000 as of December 31, 2011.
The Company's Chief Executive Officer, Dave Wentz, said, "USANA's
results in the fourth quarter were once again exceptional and cap off a
year during which we produced record top and bottom-line results every
quarter. Additionally, 2012 marks our tenth consecutive year of record
sales. We believe that our strong operating results are due to the
successful execution of our 2012 strategies. These strategies included
our worldwide personalization initiative, our effort in North America to
regain growth through strengthening our Associate sales force and our
expansion in Greater China through the consistent training of our
Associates in China on the Company's product and the implementation of a
compensation plan that is specific to that market."
Regional Results
Net sales in the Asia Pacific region increased by 21.3% to $107.8
million, compared with $88.9 million for the fourth quarter of the prior
year. This improvement was due to strong sales growth in Southeast
Asia/Pacific and Greater China. This sales growth resulted from a 17.4%
increase in the number of active Associates in Asia Pacific, as well as
price increases in certain markets that were implemented during the
first quarter of the year. Active Associate growth was again driven by
double-digit growth in Southeast Asia/Pacific and Greater China and, to
a lesser extent, the addition of the Thailand market to the region.
"Our Asia Pacific region continued to drive our business during the
fourth quarter. We remain pleased with the strong growth in our leading
markets in Greater China and Southeast Asia/Pacific, and we were
especially encouraged by the growth in sales on a local currency basis
that we generated in every market in Asia Pacific this quarter,"
continued Mr. Wentz. "We are gaining traction in China and,
consequently, our Greater China growth strategy will continue to be a
key initiative for the Company in 2013 and beyond."
During the fourth quarter of 2012, net sales in the North America/Europe
region increased by 6.4% to $60.7 million, compared with $57.1 million
in the prior-year period. The number of Active Associates in North
America/Europe was essentially flat compared with the fourth quarter of
2011.
Mr. Wentz added, "We made solid progress in North America during 2012
and have seen a noticeable improvement in our operating trends in this
region. We generated strong results in Mexico during the year, where net
sales improved 25.7% and Active Associates increased 20.0%. We foresee
growth in our U.S. and Canada markets as we continue to focus on
initiatives aimed at generating active customer growth."
The Company maintained its successful track record of generating
meaningful levels of cash from operations and ended the quarter with $71
million in cash and cash equivalents. Cash generated from operations
totaled $29.2 million for the quarter. During the quarter, the Company
invested $32.8 million to repurchase 767,000 shares of the Company's
stock.
2012 Results
For the year ended December 29, 2012, net sales increased by 11.5% to
$648.7 million, compared with $581.9 million in the prior year. Net
sales growth was driven by increases in both Asia Pacific and North
America/Europe regions. Changes in currency exchange rates did not have
a meaningful impact on sales for the year as a whole.
Net earnings for the year ended December 29, 2012 increased by 30.9% to
$66.4 million, or $4.45 per share, compared with $3.26 per share in the
prior year. The increase in net earnings was due primarily to higher net
sales, lower relative Associate incentive expense, and a lower effective
tax rate of 32.5% for the full year.
Cash generated from operations totaled $92.8 million for the year ended
December 29, 2012. The Company repurchased 1.6 million shares in 2012
for a total investment of $68.3 million. The Company ended the year debt
free with a remaining share repurchase authorization of approximately
$32 million.
"USANA's performance in 2012 was excellent and we look forward to
executing our 2013 growth strategy," concluded Mr. Wentz. "Our primary
objective in 2013 will be to grow our active customer counts in each of
our regions. To achieve this objective, we have a number of initiatives
planned at both the individual market and regional level. In certain of
our mature markets, for example, we will execute a pricing initiative
that is designed to make it easier for our Associate sales force to
bring new customers into the business. This initiative will likely
result in some short-term pressure on our top and bottom-line results in
these markets, but should also create much greater potential for
long-term customer growth. At the regional level, we will continue to
execute our North America and Greater China growth strategies and will
also expand our personalization initiative worldwide. With the
successful execution of these strategies, I expect 2013 to be another
record year for USANA."
Outlook
The Company provided the following financial outlook for 2013:
-
Consolidated net sales between $700 million and $720 million.
-
Earnings per share between $5.10 and $5.25.
Chief Financial Officer Paul Jones commented, "Our fourth quarter
top-and-bottom line results represent a solid finish to an excellent
year. With our strong financial performance and increasing cash flow, we
have the flexibility to invest in several key business initiatives
during 2013. One of these efforts will be our pricing initiative, which
is designed to generate customer growth in several of our mature
markets. Although this initiative will require some upfront investment,
as well as patience to execute, we believe that it is the right
investment at the right time to generate customer growth in these
markets. In 2013, we will also continue to invest in our personalization
strategy, international expansion, and vertical integration
opportunities to gain efficiencies and improve margins. As represented
by our outlook for 2013, we anticipate continued growth in sales and
earnings in 2013, and we expect to report another consecutive year of
record-breaking results."
Conference Call
USANA will hold a conference call and webcast to discuss this
announcement with investors on Wednesday, February 6, 2013 at 11:00 AM
Eastern Time. Investors may listen to the call by accessing USANA's
website at http://www.usanahealthsciences.com.
About USANA
USANA develops and manufactures high-quality nutritional, personal care,
and weight-management products that are sold directly to Associates and
Preferred Customers throughout the United States, Canada, Australia, New
Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore,
Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom,
Thailand, France and Belgium. More information on USANA can be found at http://www.usanahealthsciences.com.
Safe Harbor
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Our actual results could differ materially from
those projected in these forward-looking statements, which involve a
number of risks and uncertainties, including global economic conditions
generally, reliance upon our network of independent Associates, the
governmental regulation of our products, manufacturing and marketing
risks, adverse publicity risks, and risks associated with our
international expansion. The contents of this release should be
considered in conjunction with the risk factors, warnings, and
cautionary statements that are contained in our most recent filings with
the Securities and Exchange Commission.
|
USANA Health Sciences, Inc.
|
|
Consolidated Statements of Earnings
|
|
(In thousands, except per share data)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
|
Year Ended
|
|
|
|
|
|
31-Dec-11
|
|
|
29-Dec-12
|
|
|
|
31-Dec-11
|
|
|
29-Dec-12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
|
|
|
$
|
145,947
|
|
|
|
$
|
168,530
|
|
|
|
$
|
581,939
|
|
|
$
|
648,726
|
|
Cost of sales
|
|
|
|
|
24,620
|
|
|
|
|
30,171
|
|
|
|
|
101,692
|
|
|
|
115,804
|
|
Gross profit
|
|
|
|
|
121,327
|
|
|
|
|
138,359
|
|
|
|
|
480,247
|
|
|
|
532,922
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Associate incentives
|
|
|
|
|
67,203
|
|
|
|
|
71,190
|
|
|
|
|
265,928
|
|
|
|
280,506
|
|
Selling, general and administrative
|
|
|
|
|
34,025
|
|
|
|
|
39,087
|
|
|
|
|
137,063
|
|
|
|
154,237
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings from operations
|
|
|
|
|
20,099
|
|
|
|
|
28,082
|
|
|
|
|
77,256
|
|
|
|
98,179
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
|
|
(12
|
)
|
|
|
|
70
|
|
|
|
|
222
|
|
|
|
247
|
|
Earnings before income taxes
|
|
|
|
|
20,087
|
|
|
|
|
28,152
|
|
|
|
|
77,478
|
|
|
|
98,426
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income taxes
|
|
|
|
|
6,926
|
|
|
|
|
9,705
|
|
|
|
|
26,726
|
|
|
|
31,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NET (News - Alert) EARNINGS
|
|
|
|
$
|
13,161
|
|
|
|
$
|
18,447
|
|
|
|
$
|
50,752
|
|
|
$
|
66,433
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share - diluted
|
|
|
|
$
|
0.87
|
|
|
|
$
|
1.27
|
|
|
|
$
|
3.26
|
|
|
$
|
4.45
|
|
Weighted average shares outstanding - diluted
|
|
|
|
|
15,177
|
|
|
|
|
14,471
|
|
|
|
|
15,574
|
|
|
|
14,923
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
USANA Health Sciences, Inc.
|
|
Consolidated Balance Sheets
|
|
(In thousands)
|
|
(Unaudited)
|
|
|
|
|
|
As of
|
|
|
|
As of
|
|
|
|
|
|
31-Dec-11
|
|
|
|
29-Dec-12
|
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
$
|
50,353
|
|
|
|
$
|
70,839
|
|
Inventories
|
|
|
|
|
36,968
|
|
|
|
|
36,481
|
|
Other current assets
|
|
|
|
|
18,738
|
|
|
|
|
25,225
|
|
Total current assets
|
|
|
|
|
106,059
|
|
|
|
|
132,545
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
|
|
60,754
|
|
|
|
|
61,751
|
|
Goodwill
|
|
|
|
|
17,740
|
|
|
|
|
17,890
|
|
Intangible assets, net
|
|
|
|
|
42,637
|
|
|
|
|
42,085
|
|
Deferred income taxes
|
|
|
|
|
11,033
|
|
|
|
|
5,956
|
|
Other assets
|
|
|
|
|
6,273
|
|
|
|
|
7,128
|
|
Total assets
|
|
|
|
$
|
244,496
|
|
|
|
$
|
267,355
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
|
$
|
7,952
|
|
|
|
$
|
7,040
|
|
Other current liabilities
|
|
|
|
|
51,744
|
|
|
|
|
63,804
|
|
Total current liabilities
|
|
|
|
|
59,696
|
|
|
|
|
70,844
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other long-term liabilities
|
|
|
|
|
942
|
|
|
|
|
938
|
|
Deferred income taxes
|
|
|
|
|
9,948
|
|
|
|
|
10,001
|
|
Stockholders' equity
|
|
|
|
|
173,910
|
|
|
|
|
185,572
|
|
Total liabilities and stockholders' equity
|
|
|
|
$
|
244,496
|
|
|
|
$
|
267,355
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
USANA Health Sciences, Inc.
|
|
Sales by Region
|
|
(Unaudited)
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended
|
|
|
|
|
|
31-Dec-11
|
|
|
|
29-Dec-12
|
|
Region
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America / Europe
|
|
|
|
$
|
57,070
|
|
|
39.1
|
%
|
|
|
|
$
|
60,747
|
|
|
36.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Southeast Asia/Pacific
|
|
|
|
|
29,411
|
|
|
20.2
|
%
|
|
|
|
|
37,419
|
|
|
22.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Greater China
|
|
|
|
|
52,021
|
|
|
35.6
|
%
|
|
|
|
|
62,499
|
|
|
37.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North Asia
|
|
|
|
|
7,445
|
|
|
5.1
|
%
|
|
|
|
|
7,865
|
|
|
4.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific Total
|
|
|
|
|
88,877
|
|
|
60.9
|
%
|
|
|
|
|
107,783
|
|
|
64.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
$
|
145,947
|
|
|
100.0
|
%
|
|
|
|
$
|
168,530
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Active Associates by Region (1)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
|
|
31-Dec-11
|
|
|
|
29-Dec-12
|
|
Region
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America / Europe
|
|
|
|
|
78,000
|
|
|
35.1
|
%
|
|
|
|
|
78,000
|
|
|
31.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Southeast Asia/Pacific
|
|
|
|
|
49,000
|
|
|
22.1
|
%
|
|
|
|
|
58,000
|
|
|
23.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Greater China
|
|
|
|
|
86,000
|
|
|
38.7
|
%
|
|
|
|
|
103,000
|
|
|
41.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North Asia
|
|
|
|
|
9,000
|
|
|
4.1
|
%
|
|
|
|
|
8,000
|
|
|
3.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific Total
|
|
|
|
|
144,000
|
|
|
64.9
|
%
|
|
|
|
|
169,000
|
|
|
68.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
222,000
|
|
|
100.0
|
%
|
|
|
|
|
247,000
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Associates are independent distributors of our products who
also purchase our products for their personal use. We only
count as active those Associates who have purchased product at any time
during the most recent three-month period, either for personal use
or for resale.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Active Preferred Customers by Region (2)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
|
|
31-Dec-11
|
|
|
|
29-Dec-12
|
|
Region
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North America / Europe
|
|
|
|
|
52,000
|
|
|
81.3
|
%
|
|
|
|
|
53,000
|
|
|
82.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Southeast Asia/Pacific
|
|
|
|
|
6,000
|
|
|
9.4
|
%
|
|
|
|
|
6,000
|
|
|
9.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Greater China
|
|
|
|
|
5,000
|
|
|
7.8
|
%
|
|
|
|
|
4,000
|
|
|
6.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
North Asia
|
|
|
|
|
1,000
|
|
|
1.5
|
%
|
|
|
|
|
1,000
|
|
|
1.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asia Pacific Total
|
|
|
|
|
12,000
|
|
|
18.8
|
%
|
|
|
|
|
11,000
|
|
|
17.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
64,000
|
|
|
100.0
|
%
|
|
|
|
|
64,000
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Preferred Customers purchase our products strictly for their
personal use and are not permitted to resell or to distribute
the products. We only count as active those Preferred Customers
who have purchased product at any time during the most recent
three-month period.
|

[ Back To TMCnet.com's Homepage ]
|